An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma

The advent of dose intensified interval compressed therapy has improved event-free survival for patients with localized Ewing sarcoma (EwS) to 78% at 5 years. However, nearly a quarter of patients with localized tumors and 60–80% of patients with metastatic tumors suffer relapse and die of disease....

Descripción completa

Detalles Bibliográficos
Autores principales: Shulman, David S., Whittle, Sarah B., Surdez, Didier, Bailey, Kelly M., de Álava, Enrique, Yustein, Jason T., Shlien, Adam, Hayashi, Masanori, Bishop, Alexander J. R., Crompton, Brian D., DuBois, Steven G., Shukla, Neerav, Leavey, Patrick J., Lessnick, Stephen L., Kovar, Heinrich, Delattre, Olivier, Grünewald, Thomas G. P., Antonescu, Cristina R., Roberts, Ryan D., Toretsky, Jeffrey A., Tirode, Franck, Gorlick, Richard, Janeway, Katherine A., Reed, Damon, Lawlor, Elizabeth R., Grohar, Patrick J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482616/
https://www.ncbi.nlm.nih.gov/pubmed/36115869
http://dx.doi.org/10.1038/s41698-022-00307-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482616/
https://www.ncbi.nlm.nih.gov/pubmed/36115869
http://dx.doi.org/10.1038/s41698-022-00307-2

Ejemplares similares